Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29658105 | 1.00 | CYP3A4 (0.59) | CYP3A4CTSS | |
| SCHEMBL16696084 | 0.92 | CYP3A4 (0.53) | CYP3A4CTSS | |
| SCHEMBL30110668 | 0.90 | CYP3A4 (0.59) | CYP3A4CTSS | |
| SCHEMBL9940698 | 0.90 | CYP3A4 (0.59) | CYP3A4CTSS | |
| SCHEMBL31069427 | 0.89 | CYP3A4 (0.57) | CYP3A4 | |
| SCHEMBL15551802 | 0.88 | CYP3A4 (0.44) | CYP3A4CTSS | |
| SCHEMBL17613273 | 0.87 | CYP3A4 (0.60) | CYP3A4 | |
| SCHEMBL16819105 | 0.87 | CYP3A4 (0.44) | CYP3A4CTSS | |
| SCHEMBL9940617 | 0.86 | CYP3A4 (0.62) | CYP3A4 | |
| SCHEMBL9940484 | 0.86 | CYP3A4 (0.46) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892273-A2 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-13 | — | — | EP | claimed |
| US-20190054084-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-21 | — | — | US | claimed |
| EP-3411028-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | Janssen Sciences Ireland UC (IE) | 2018-12-12 | — | — | EP | claimed |
| WO-2017134133-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | WO | claimed |
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2024-05-16 | — | — | US | disclosed |
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2023-07-25 | — | — | US | disclosed |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) | 2022-11-08 | — | — | US | disclosed |
| EP-3887372-B1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-10-12 | — | — | EP | disclosed |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | Janssen Sciences Ireland Unlimited Company (IE) | 2022-05-24 | — | — | US | disclosed |
| EP-3717486-B1 | PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-03-23 | — | — | EP | disclosed |
| CN-113874380-A | Other heteroaromatic compounds with anti-RSV activity | 爱尔兰詹森科学公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-3411028-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | Janssen Sciences Ireland UC (IE) | 2018-12-12 | — | — | EP | disclosed |
| EP-3411028-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | Janssen Sciences Ireland UC (IE) | 2018-12-12 | — | — | EP | disclosed |
| EP-3288942-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | Janssen Sciences Ireland UC (IE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017134133-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134133-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017134133-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016174079-A1 | RSV ANTIVIRAL PYRAZOLO- AND TRIAZOLO-PYRIMIDINE COMPOUNDS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-03 | — | — | WO | disclosed |
| EP-2651903-B1 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190054084-A1 | COMBINATION PRODUCTS FOR THE TREATMENT OF RSV | MTNR1A, GPR88, MTPN | CYP3A4 3882/4885CTSS 2488/4885 |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | ACE, ACE2, PTBP1 | CYP3A4 272/4885CTSS 618/4885 |
| US-11339165-B2 | Pyrazolopyrimidines having activity against the respiratory syncytial virus (RSV) | RRP15, MAVS, ACE | CYP3A4 154/4885CTSS 2104/4885 |
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | MAVS, ZC3HAV1, RNASEH1 | CYP3A4 69/4885CTSS 496/4885 |
| US-11708369-B2 | Heteroaromatic compounds having activity against RSV | MAVS, ZC3HAV1, SARS1 | CYP3A4 58/4885CTSS 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.